Â鶹ŮÓÅ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Â鶹ŮÓÅ Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Jul 22 2025

Full Issue

Sarepta Suspends Elevidys Shipments After Pressure From FDA, Hospitals

Sarepta's pause on its prescription gene therapy drug for Duchenne muscular dystrophy gives the company time to work with the FDA on reviews. Infusions nationwide will be canceled. Also in the news, AstraZeneca, Sanofi, Humana, UnitedHealth, and more.

Sarepta Therapeutics said Monday evening it will pause all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, acceding to a request made by the Food and Drug Administration after several patient deaths. It’s a surprising reversal by Sarepta. The company had initially rejected the agency’s request, which was issued Friday. (Feuerstein and Mast, 7/21)

Under pressure of tariffs and price controls from the Trump administration, AstraZeneca announced Monday that it would invest $50 billion by 2030.AstraZeneca’s CEO, Pascal Soriot, flanked by Trump administration officials and Virginia Gov. Glenn Youngkin, added that, as part of the investment, the company would build a multi-billion-dollar manufacturing site in Virginia. (Payne, 7/21)

Medtech may be one of the few sectors in healthcare that stands to benefit from the new tax law. The Medicaid cuts law includes incentives for companies’ research and development activities and capital investments. The provisions apply to all companies, and could mean expanded financial support for medtech startups and more cash in the near term for companies of all sizes. (Dubinsky, 7/21)

Sanofi agreed to buy UK biotech Vicebio Ltd. for as much as $1.6 billion, gaining experimental vaccines and a technology to streamline their development. The French drugmaker will pay $1.15 billion upfront with a commitment for potential milestones worth as much as $450 million, it said in a statement Tuesday. (Petroff and Furlong, 7/22)

Insurance industry —

Humana refiled a lawsuit Monday evening against the federal government, as the health insurance giant pushes to keep billions of dollars that could vanish as a result of downgraded ratings tied to its Medicare Advantage plans. (Herman, 7/22)

UnitedHealthcare is rolling out a new benefit to encourage preventive cancer screenings. The insurer's new breast and colon cancer detection benefit will be available for eligible commercial plans starting Jan. 1, 2026. Through the program, UHC will cover members' first diagnostic imaging tests for breast cancer and diagnostic tests for colon cancer. (Minemyer, 7/21)

Medicaid-focused startup Fortuna Health has raised $18 million in a Series A funding round, the company announced Monday. The round was led by Andreessen Horowitz. Y Combinator, the startup accelerator that helped launch Airbnb and Instacart, also participated, along with the founders of artificial intelligence company Abridge, insurtech Oscar Health and primary care company One Medical (now part of Amazon). (Perna, 7/21)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
  • Wednesday, April 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 Â鶹ŮÓÅ